Patent · US Active

Roflumilast for the treatment of pulmonary hypertension

US8648100B2 · kind B2 · utility

0Cited by

4References

5Claims

0Family size

Assignee

TAKEDA GMBH · DE

Inventors

Rolf Beume · Konstanz, DE
Armin Hatzelmann · Konstanz, DE
Degenhard Marx · Radebeul, DE
Christian Schudt · Konstanz, DE
Hermann Tenor · Konstanz, DE
Saadia Eddahibi · Paris, FR
Serge Adnot · Châteauroux, FR

Key dates

Filing date	Apr 12, 2006
Grant date	Feb 11, 2014
Priority date	—
Expiry date	Oct 5, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P11/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the use of Roflumilast, Roflumilast N-Oxide or a pharmaceutically acceptable salt of either for the treatment of pulmonary hypertension. The invention additionally relates to the use of Roflumilast, Roflumilast N-oxide or a pharmaceutically acceptable salt of either in combination with a PDE5 inhibitor or a pharmaceutically acceptable salt thereof for the treatment of pulmonary hypertension.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.